Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 27, 2012. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 700,000 Ordinary shares of 25 pence each.
- Purchase Date: March 27, 2012.
- Price Range: Highest price paid was 1,435 pence per share; lowest price paid was 1,419.5 pence per share.
- Treasury Holdings (Settled): 514,997,927 shares (9.26% of total issued share capital).
- Treasury Holdings (Including Unsettled): 516,517,927 shares (10.24% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,044,004,307 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 700,000 shares for Treasury. This action increased the percentage of total voting rights held in Treasury from the prior level to 10.24% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,044,004,307) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current percentage of voting rights held in Treasury (10.24% including unsettled shares).
- Review the price paid per share (1,419.5 to 1,435 pence) against market prices on March 27, 2012.
- Check subsequent filings for the settlement status of the 1,520,000 shares purchased but not yet settled at the time of this report.